Live-attenuated vaccine against plague
US10328139B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2016 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | Jan 14, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a genetically modified Y. pestis that includes three alterations compared to a control Y. pestis. Two alterations include decreased mRNA, decreased protein, or a combination thereof, encoded by a lpp coding region and encoded by a msbB coding region. The third alteration is selected from an alteration of an intergenic region between the coding regions ypo1119 and ypo1120, and decreased mRNA, decreased protein, or a combination thereof, encoded by a coding region selected from pla, ypol717, ypmt1.80c, rbsA (ypo2500), ypo0498, vasK (ypo3603), ypo3164, hxuB (ypo3248), ypo1616, ypo1119, ypo1120, and ail. Also provided are compositions that include the genetically modified Y. pestis, and methods of using the genetically modified Y. pestis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.